ImmuneWalk Therapeutics
Modulating Immune and Inflammatory Disease by Preventing Myeloid Cells from Entering Inflamed Tissue
Company Overview
Snapshot
Founded in October 2023 by Prof Dror Harats, Sam Backenorth, and Erez Feige, ImmuneWalk Therapeutics operates with 1–10 employees. The company has raised $7 million across one funding round and recently announced positive topline Phase 1 SAD data for its immunology and inflammation drug candidate, IW-601, in June 2025.
Business overview
ImmuneWalk Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for chronic inflammatory diseases. The company's core technology, Monocyte Targeting Technology (MTT), is designed to selectively block the migration of monocytes from the bloodstream into inflamed tissues. ImmuneWalk Therapeutics serves the healthcare and life sciences sectors, specifically targeting patients with conditions such as Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Non-Alcoholic Steatohepatitis.
Strategic signal
In June 2025, ImmuneWalk Therapeutics announced positive topline Phase 1 SAD data for its immunology and inflammation drug candidate, IW-601. This clinical validation is a significant milestone, indicating the potential efficacy and safety of their Monocyte Targeting Technology. For investors, this signals strong progress in their drug development pipeline and de-risks future clinical stages, potentially accelerating the path to market for their novel therapies.
Company Intelligence Q&A
- What is ImmuneWalk Therapeutics' primary focus?
- ImmuneWalk Therapeutics focuses on developing novel therapies for chronic inflammatory diseases by preventing myeloid cells from entering inflamed tissue.
- When was ImmuneWalk Therapeutics founded and by whom?
- ImmuneWalk Therapeutics was founded in October 2023 by Prof Dror Harats, Sam Backenorth, and Erez Feige.
- What is ImmuneWalk Therapeutics' core technology?
- ImmuneWalk Therapeutics' core technology is Monocyte Targeting Technology (MTT), designed to selectively block the migration of monocytes from the bloodstream into inflamed tissues.
- What was a significant recent clinical development for ImmuneWalk Therapeutics?
- In June 2025, ImmuneWalk Therapeutics announced positive topline Phase 1 SAD data for its immunology and inflammation drug candidate, IW-601.
- What was ImmuneWalk Therapeutics' most recent funding event?
- In May 2025, ImmuneWalk Therapeutics announced a $7 million Seed financing round.